Cargando…

Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials

In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; and...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodersen, John, Voss, Theis, Martiny, Frederik, Siersma, Volkert, Barratt, Alexandra, Heleno, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078745/
https://www.ncbi.nlm.nih.gov/pubmed/32194774
http://dx.doi.org/10.1183/20734735.0013-2020
_version_ 1783507684895490048
author Brodersen, John
Voss, Theis
Martiny, Frederik
Siersma, Volkert
Barratt, Alexandra
Heleno, Bruno
author_facet Brodersen, John
Voss, Theis
Martiny, Frederik
Siersma, Volkert
Barratt, Alexandra
Heleno, Bruno
author_sort Brodersen, John
collection PubMed
description In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; and 3) eligible screening participants have a high risk of dying from causes other than lung cancer. The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time bias and without contamination of the control group. Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because lung cancer incidence after the end of screening was not published. Two other RCTs using active comparators were also excluded. Therefore, five RCTs were included: two trials were at low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-detected cancers were overdiagnosed. There is uncertainty about this substantial degree of overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate across the two trials. KEY POINTS: Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were identified; five were included for meta-analysis but only two of those were at low risk of bias. In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed. There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained heterogeneity and low precision of the point estimate. If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial. EDUCATIONAL AIMS: To appreciate that low-dose computed tomography screening for lung cancer meets all three main conditions for overdiagnosis in cancer screening: a reservoir of indolent cancers exists in the population; the screening test is able to “tap” this reservoir by detecting biologically indolent cancers as well as biologically important cancers; and the population being screened is characterised by a relatively high competing risk of death from other causes. To learn about biases that might affect the estimates of overdiagnosis in randomised controlled trials in cancer screening.
format Online
Article
Text
id pubmed-7078745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-70787452020-03-19 Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials Brodersen, John Voss, Theis Martiny, Frederik Siersma, Volkert Barratt, Alexandra Heleno, Bruno Breathe (Sheff) Reviews In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; and 3) eligible screening participants have a high risk of dying from causes other than lung cancer. The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time bias and without contamination of the control group. Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because lung cancer incidence after the end of screening was not published. Two other RCTs using active comparators were also excluded. Therefore, five RCTs were included: two trials were at low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-detected cancers were overdiagnosed. There is uncertainty about this substantial degree of overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate across the two trials. KEY POINTS: Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were identified; five were included for meta-analysis but only two of those were at low risk of bias. In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed. There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained heterogeneity and low precision of the point estimate. If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial. EDUCATIONAL AIMS: To appreciate that low-dose computed tomography screening for lung cancer meets all three main conditions for overdiagnosis in cancer screening: a reservoir of indolent cancers exists in the population; the screening test is able to “tap” this reservoir by detecting biologically indolent cancers as well as biologically important cancers; and the population being screened is characterised by a relatively high competing risk of death from other causes. To learn about biases that might affect the estimates of overdiagnosis in randomised controlled trials in cancer screening. European Respiratory Society 2020-03 /pmc/articles/PMC7078745/ /pubmed/32194774 http://dx.doi.org/10.1183/20734735.0013-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Reviews
Brodersen, John
Voss, Theis
Martiny, Frederik
Siersma, Volkert
Barratt, Alexandra
Heleno, Bruno
Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title_full Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title_fullStr Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title_full_unstemmed Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title_short Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
title_sort overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078745/
https://www.ncbi.nlm.nih.gov/pubmed/32194774
http://dx.doi.org/10.1183/20734735.0013-2020
work_keys_str_mv AT brodersenjohn overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials
AT vosstheis overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials
AT martinyfrederik overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials
AT siersmavolkert overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials
AT barrattalexandra overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials
AT helenobruno overdiagnosisoflungcancerwithlowdosecomputedtomographyscreeningmetaanalysisoftherandomisedclinicaltrials